FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989706656> ?p ?o ?g. }

• W2989706656 abstract "Abstract Background Patient-reported outcomes (PROs) are important when evaluating treatment benefits in rheumatoid arthritis (RA). We compared upadacitinib, an oral, selective JAK-1 inhibitor, with placebo to assess clinically meaningful improvements in PROs in patients with RA who have had inadequate responses to biologic disease-modifying antirheumatic drugs (bDMARD-IR). Methods PRO responses between upadacitinib 15 mg or 30 mg and placebo were evaluated at week 12 from the SELECT-BEYOND trial. Improvement was determined by measuring Patient Global Assessment of Disease Activity (PtGA), pain, Health Assessment Questionnaire Disability Index (HAQ-DI), Short Form-36 Health Survey (SF-36), duration and severity of morning (AM) stiffness, and Insomnia Severity Index (ISI). Least squares mean changes and percentage of patients reporting improvements ≥ minimum clinically important differences (MCID) and scores greater than or equal to normative values were determined. The number needed to treat (NNT) to achieve clinically meaningful improvements was calculated. Results In 498 patients, both upadacitinib doses resulted in statistically significant changes from baseline versus placebo in PtGA, pain, HAQ-DI, SF-36 Physical Component Summary (PCS), 7 of 8 SF-36 domains (15 mg), 6 of 8 SF-36 domains (30 mg), and AM stiffness duration and severity. Compared with placebo, more upadacitinib-treated patients reported improvements ≥ MCID in PtGA, pain, HAQ-DI, SF-36 PCS, 7 of 8 SF-36 domains (15 mg), 5 of 8 SF-36 domains (30 mg), AM stiffness duration and severity, and ISI (30 mg) and scores ≥ normative values in HAQ-DI and SF-36 domains. Across most PROs, NNTs to achieve MCID with upadacitinib ranged from 4 to 7 patients. Conclusions In bDMARD-IR RA patients, upadacitinib (15 mg or 30 mg) improved multiple aspects of quality of life, and more patients reached clinically meaningful improvements approaching normative values compared with placebo. Trial registration The trial is registered with ClinicalTrials.gov (NCT02706847), registered 6 March 2016." @default.
• W2989706656 created "2019-12-05" @default.
• W2989706656 creator A5012283576 @default.
• W2989706656 creator A5021102788 @default.
• W2989706656 creator A5023213876 @default.
• W2989706656 creator A5032925081 @default.
• W2989706656 creator A5033251422 @default.
• W2989706656 creator A5037870558 @default.
• W2989706656 creator A5047233668 @default.
• W2989706656 creator A5052170557 @default.
• W2989706656 creator A5085676518 @default.
• W2989706656 creator A5088741186 @default.
• W2989706656 date "2019-12-01" @default.
• W2989706656 modified "2023-10-06" @default.
• W2989706656 title "Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs" @default.
• W2989706656 cites W1564667278 @default.
• W2989706656 cites W1807077095 @default.
• W2989706656 cites W182910583 @default.
• W2989706656 cites W1904849135 @default.
• W2989706656 cites W1937361486 @default.
• W2989706656 cites W1957937187 @default.
• W2989706656 cites W1970459010 @default.
• W2989706656 cites W1973470095 @default.
• W2989706656 cites W1975923077 @default.
• W2989706656 cites W1976591039 @default.
• W2989706656 cites W1982094716 @default.
• W2989706656 cites W1993135797 @default.
• W2989706656 cites W1993254952 @default.
• W2989706656 cites W2006616048 @default.
• W2989706656 cites W2014709373 @default.
• W2989706656 cites W2019616141 @default.
• W2989706656 cites W2026720490 @default.
• W2989706656 cites W2037377025 @default.
• W2989706656 cites W2050616272 @default.
• W2989706656 cites W2058819522 @default.
• W2989706656 cites W2064408454 @default.
• W2989706656 cites W2074018301 @default.
• W2989706656 cites W2082850379 @default.
• W2989706656 cites W2089468569 @default.
• W2989706656 cites W2091055562 @default.
• W2989706656 cites W2104843608 @default.
• W2989706656 cites W2106216235 @default.
• W2989706656 cites W2116710724 @default.
• W2989706656 cites W2117642771 @default.
• W2989706656 cites W2120393706 @default.
• W2989706656 cites W2125991357 @default.
• W2989706656 cites W2130240143 @default.
• W2989706656 cites W2131592263 @default.
• W2989706656 cites W2147285403 @default.
• W2989706656 cites W2152721471 @default.
• W2989706656 cites W2161137669 @default.
• W2989706656 cites W2162260707 @default.
• W2989706656 cites W2289065863 @default.
• W2989706656 cites W2315394641 @default.
• W2989706656 cites W2380226057 @default.
• W2989706656 cites W2416506154 @default.
• W2989706656 cites W2460850519 @default.
• W2989706656 cites W2467897053 @default.
• W2989706656 cites W2508096544 @default.
• W2989706656 cites W2540497002 @default.
• W2989706656 cites W2540974094 @default.
• W2989706656 cites W2559407770 @default.
• W2989706656 cites W2559743688 @default.
• W2989706656 cites W2593835974 @default.
• W2989706656 cites W2767201644 @default.
• W2989706656 cites W2772042989 @default.
• W2989706656 cites W2807791746 @default.
• W2989706656 cites W2808333862 @default.
• W2989706656 cites W2808428727 @default.
• W2989706656 cites W4211111012 @default.
• W2989706656 cites W4292806894 @default.
• W2989706656 cites W65909262 @default.
• W2989706656 doi "https://doi.org/10.1186/s13075-019-2059-8" @default.
• W2989706656 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6889334" @default.
• W2989706656 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31791386" @default.
• W2989706656 hasPublicationYear "2019" @default.
• W2989706656 type Work @default.
• W2989706656 sameAs 2989706656 @default.
• W2989706656 citedByCount "27" @default.
• W2989706656 countsByYear W29897066562020 @default.
• W2989706656 countsByYear W29897066562021 @default.
• W2989706656 countsByYear W29897066562022 @default.
• W2989706656 crossrefType "journal-article" @default.
• W2989706656 hasAuthorship W2989706656A5012283576 @default.
• W2989706656 hasAuthorship W2989706656A5021102788 @default.
• W2989706656 hasAuthorship W2989706656A5023213876 @default.
• W2989706656 hasAuthorship W2989706656A5032925081 @default.
• W2989706656 hasAuthorship W2989706656A5033251422 @default.
• W2989706656 hasAuthorship W2989706656A5037870558 @default.
• W2989706656 hasAuthorship W2989706656A5047233668 @default.
• W2989706656 hasAuthorship W2989706656A5052170557 @default.
• W2989706656 hasAuthorship W2989706656A5085676518 @default.
• W2989706656 hasAuthorship W2989706656A5088741186 @default.
• W2989706656 hasBestOaLocation W29897066561 @default.
• W2989706656 hasConcept C111278954 @default.
• W2989706656 hasConcept C126322002 @default.
• W2989706656 hasConcept C142724271 @default.
• W2989706656 hasConcept C168563851 @default.
• W2989706656 hasConcept C1862650 @default.
• W2989706656 hasConcept C198451711 @default.

• next